ACORQ vs. SQZ, SCNI, PKBO, WINT, GMDAQ, BTTX, PTEIQ, OSAP, OSA, and ADTX
Should you be buying Acorda Therapeutics stock or one of its competitors? The main competitors of Acorda Therapeutics include SQZ Biotechnologies (SQZ), Scinai Immunotherapeutics (SCNI), Peak Bio (PKBO), Windtree Therapeutics (WINT), Gamida Cell (GMDAQ), Better Therapeutics (BTTX), PolarityTE (PTEIQ), ProSomnus (OSAP), ProSomnus (OSA), and Aditxt (ADTX). These companies are all part of the "medical" sector.
Acorda Therapeutics (NASDAQ:ACORQ) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, community ranking, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.
SQZ Biotechnologies received 10 more outperform votes than Acorda Therapeutics when rated by MarketBeat users.
Acorda Therapeutics has a net margin of -227.75% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Acorda Therapeutics' return on equity.
In the previous week, Acorda Therapeutics had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for Acorda Therapeutics and 0 mentions for SQZ Biotechnologies. SQZ Biotechnologies' average media sentiment score of 0.00 beat Acorda Therapeutics' score of -0.95 indicating that SQZ Biotechnologies is being referred to more favorably in the news media.
12.7% of Acorda Therapeutics shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 2.6% of Acorda Therapeutics shares are held by insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Acorda Therapeutics has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500.
SQZ Biotechnologies has lower revenue, but higher earnings than Acorda Therapeutics. SQZ Biotechnologies is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
SQZ Biotechnologies beats Acorda Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Acorda Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACORQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACORQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ACORQ vs. The Competition
Acorda Therapeutics Competitors List
Related Companies and Tools
